El papel de B2M en el diagnóstico precoz de enfermedad renal crónica (ERC): una revisión sistemática y metaanálisis en 6 378 pacientes
Imperium Académico Multidisciplinary Journal · 11.03.2026 · 3 (1) · 1-16
DOI: 10.63969/r649gg24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Imperium Académico Multidisciplinary Journal, online erschienen am 11.03.2026. Verfasst von Domenica Fiorella Quevedo Mieles und 7 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Chronic kidney disease (CKD) affects more than 10% of the global population and represents one of the leading causes of mortality worldwide. Early detection is crucial, particularly in older adults, since serum creatinine loses diagnostic sensitivity in this population. β2-microglobulin (β2-M), being independent of muscle mass and reflecting early proximal tubular injury, has been proposed as a complementary biomarker to creatinine.
Objective
To evaluate the diagnostic accuracy of β2-microglobulin (β2-M) for the early detection of CKD in adults.
Methods
A systematic review (SR) and meta-analysis (MA) were conducted using bibliographic databases including PubMed, Scopus, and ScienceDirect (2014–2024). Randomized controlled trials (RCTs), cohort studies, and cross-sectional studies reporting β2-M levels (mg/L) and glomerular filtration rate (GFR) were included. Data were analyzed using random-effects models with restricted maximum likelihood estimation (REML) and Hartung-Knapp-Sidik-Jonkman correction. Heterogeneity was assessed using the I² statistic.
Results
A total of 2,778 articles were screened; 15 were included in the systematic review and 7 in the meta-analysis. The pooled sample comprised 6,378 participants (3,190 with CKD and 3,188 without CKD). The prevalence of CKD among individuals with elevated β2-M was 41%. The pooled relative risk (RR) was 3.25 (95% CI: 1.68–6.29; p=0.005). Patients with elevated β2-M levels had approximately three times the risk of developing CKD compared with those with normal values. High heterogeneity was observed among the analyzed populations (I² = 96%). Moderate variability (Tau² = 0.41) suggests partial consistency of the estimated effect. The association between β2-M and CKD is consistent and physiologically plausible, as elevated β2-M levels predict renal deterioration and mortality in clinical settings. Additionally, β2-M may complement traditional renal biomarkers such as creatinine and cystatin C. Conclusion: β2-microglobulin is a promising biomarker for the early diagnosis of CKD; however, it should be used as a complementary marker within the standard renal function assessment panel.
Zitieren
APA
Mieles, D. F. Q., Castro, C. X. C., Castro, R. M. O., Leon, J. L. R., Santillán, A. R. J., Cruz, A. V. I. D. L., Vela, M. A. A., & Ulloa, I. R. G. (2026). El papel de B2M en el diagnóstico precoz de enfermedad renal crónica (ERC): una revisión sistemática y metaanálisis en 6 378 pacientes. Imperium Académico Multidisciplinary Journal, 3(1), 1-16. https://doi.org/10.63969/r649gg24
Vancouver
Mieles DFQ, Castro CXC, Castro RMO, Leon JLR, Santillán ARJ, Cruz AVIDL, et al. El papel de B2M en el diagnóstico precoz de enfermedad renal crónica (ERC): una revisión sistemática y metaanálisis en 6 378 pacientes. Imperium Académico Multidisciplinary Journal. 2026;3(1):1-16. doi:10.63969/r649gg24
BibTeX
@article{Mieles2026,
author = {Mieles, Domenica Fiorella Quevedo and Castro, Carlos Xavier Caicedo and Castro, Ronald Moises Orellana and Leon, Johanna Lizbeth Reyes and Santillán, Ariana Romina Jaramillo and Cruz, Alexandra Vanessa Illanes De La and Vela, Melissa Andrea Aragundi and Ulloa, Israel Rollin Guerrero},
title = {El papel de B2M en el diagnóstico precoz de enfermedad renal crónica (ERC): una revisión sistemática y metaanálisis en 6 378 pacientes},
journal = {Imperium Académico Multidisciplinary Journal},
year = {2026},
volume = {3},
number = {1},
pages = {1--16},
doi = {10.63969/r649gg24}
}
EUVIMED